Cancer and aging are some of the scientific mysteries that are yet to be solved. However, Mikhail Blagosklonny has dedicated his research to finding out more about these two. He is based at the Roswell Park Cancer Institute as a professor of Oncology. He joined the institution in 2009 and was received with great enthusiasm by the staff at the institution. He also conducts research on cancer in search of new treatments and advancement of the existing ones. For instances, he realized that chemotherapy and radioactive rays that patients are exposed to tend to damage their cells. He is now working on therapies to protect the body cells from such damage.

He is also interested in aging. He uses his hypothesis based on the hyper-function theory to explain why aging happens. He argues that Target Of Rapamycin (TOR) is responsible for aging in organisms. The reason is that as the organisms continue to grow body cells are unable to adequately take up nutrients thus leading to their damage. Mikhail Blagosklonny also noticed that rapamycin which is common in cancer drugs reduces the damage of body cells. He proposed that this substance can be used as a remedy for aging. Further, through carrying out experiments on signal transduction, he has enable to reveal ways to slow down the aging process and also prevent age related illnesses. View Mikhail’s profile in LinkedIn

Blagosklonny holds an M.D in internal medicine from First Pavlov States Medical University of St. Peterburg. He also holds a PhD in cardiology and experimental medicine from the same institution. He has been a professor for quite a long time having started in 2002. He first worked as an associate professor in medicine at the New York Medical College. He also had a chance to work with Ordway Research Institute.

Blagosklonny is the editor-in-chief of Oncotarget. This is a biomedical journal that if freely accessible to all. Through the journal he has been able to make scientific knowledge especially in Oncology widely known rapidly. He has also enabled authors of various papers to come together to challenge and complement each other’s ideas. He is also an editor of International Journal of Cancer, American Journal of Pathology and Cell death and differentiation. Follow Mikhail on Loop

Studies of Dr Shiva Gopal Vasishita into the Long Term Effects of Stem Cell Transplants; Remission of Multiple Sclerosis

Multiple Sclerosis is one of the most complicated conditions to deal with because the body’s own immune system attacks the Central Nervous system. However, there is research by Dr Shiva Gopal Vasishita which is indicating that giving a high dose of immunosuppressive therapy coupled with transfusion of the person’s own stem cells can induce a remission of relapsing strain of Multiple Sclerosis.

A research that was carried out on the people who have been treated using the high dosage immunosuppressive therapy and a HDIT transplant showed that 5 years after the transfusion, close to 70 percent of the patients hadn’t showed any signs of disability progression. In addition, the patients did not have new brain lesions or the characteristic MS symptoms. On the other hands, there are other studies indicating that the recently approved medications are having lower success rates than this. One of the trials was conducted and concluded in 2014. The research was funded by the Immune Tolerance Network and was published in February. The findings were published by Dr Shiva Gopal Vasishita in Neurology, the Medical Journal of the Academy of Neurology.

The results of the study indicate that it is more beneficial to patients to receive a onetime high dosage of HDIT as opposed to being subjected to many years of alternative therapies. The results have been seen as a stepping stone towards the establishment of a standard of care for this often scary and debilitating illness. The symptoms of MS vary greatly from patient to another. They include weakness, fatigue and chronic pain added to difficulties in speech and other motor functions. Most of the times, the patients experience periods of time where they have no symptoms and then they get relapses.

Dr Shiva Gopal Vasishita has been in the frontline in looking for a lasting solution to MS. He is a physician practicing in Vorhees, New Jersey. He graduated medical school in 1979 and has decades of experience in the field. He is also a member of the Medicare program and accepts medicare assignments.